Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 416,742 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 268 · Balance 416,742 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2019 Filed Mar 6, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,700 | $54.64 | $202,168.00 |
DisclosureSEC source: 0001209191-19-017328 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,325 F2 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,700 shares in multiple trades at prices ranging from $54.37 to $55.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 16,268 | $14.37 | $233,771.16 |
DisclosureSEC source: 0001209191-19-017328 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-015566 · doc4.xml · derivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,877 Underlying: Ordinary Shares · 100,000 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,903 | $56.49 | $389,922.86 |
DisclosureSEC source: 0001209191-19-015566 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,757 F4 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,903 shares in multiple trades at prices ranging from $56.37 to $56.58. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 55,815 | $55.85 | $3,117,156.12 |
DisclosureSEC source: 0001209191-19-015566 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,660 F3 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 55,815 shares in multiple trades at prices ranging from $55.37 to $56.36. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 37,282 | $54.97 | $2,049,503.39 |
DisclosureSEC source: 0001209191-19-015566 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,475 F2 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 37,282 shares in multiple trades at prices ranging from $54.37 to $55.36. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $14.37 | $1,437,000.00 |
DisclosureSEC source: 0001209191-19-015566 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 903 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-014993 · doc4.xml · derivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,887 Underlying: Ordinary Shares · 903 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 903 | $54.40 | $49,118.69 |
DisclosureSEC source: 0001209191-19-014993 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,757 F2 · price: On February 28, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 903 shares in multiple trades at prices ranging from $54.37 to $54.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 903 | $14.37 | $12,976.11 |
DisclosureSEC source: 0001209191-19-014993 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014993 · doc4.xml · derivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,518 Underlying: Ordinary Shares · 9,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,260 | $52.90 | $489,854.00 |
DisclosureSEC source: 0001209191-19-014993 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:51 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 53,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013676 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,333 Underlying: Ordinary Shares · 53,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:51 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 53,333 | $53.38 | $2,846,915.54 |
DisclosureSEC source: 0001209191-19-013676 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,902 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · derivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 17,902 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 17,902 | $51.46 | $921,236.92 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,902 | $11.46 | $205,156.92 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 32,098 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · derivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,902 Underlying: Ordinary Shares · 32,098 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 32,098 | $51.46 | $1,651,763.08 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 32,098 | $11.46 | $367,843.08 |
DisclosureSEC source: 0001209191-19-010273 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 88,695 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001209191-19-005317 · doc4.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 88,695 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 88,695 | $47.48 | $4,211,238.60 |
DisclosureSEC source: 0001209191-19-005317 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F2 · price: On January 23, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 88,695 shares in multiple trades at prices ranging from $47.48 to $47.49. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 88,695 | $7.48 | $663,438.60 |
DisclosureSEC source: 0001209191-19-005317 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 46,863 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-004782 · doc4.xml · derivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 46,863 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,644 | $46.16 | $629,793.40 |
DisclosureSEC source: 0001209191-19-004782 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F3 · price: On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 13,644 shares in multiple trades at prices ranging from $46.06 to $46.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 33,219 | $45.80 | $1,521,563.08 |
DisclosureSEC source: 0001209191-19-004782 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,808 F2 · price: On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 33,219 shares in multiple trades at prices ranging from $45.06 to $46.05. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 46,863 | $3.44 | $161,208.72 |
DisclosureSEC source: 0001209191-19-004782 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · derivative · entry 7 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,863 Underlying: Ordinary Shares · 100,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100,000 | $45.26 | $4,526,400.00 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F4 · price: On January 17, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $44.90 to $45.55. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $3.44 | $344,000.00 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · derivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,863 Underlying: Ordinary Shares · 100,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,787 | $45.28 | $80,906.43 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F3 · price: On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,787 shares in multiple trades at prices ranging from $45.25 to $45.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 98,213 | $45.05 | $4,424,397.44 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,951 F2 · price: On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 98,213 shares in multiple trades at prices ranging from $44.25 to $45.24. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $3.44 | $344,000.00 |
DisclosureSEC source: 0001209191-19-004550 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · derivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,863 Underlying: Ordinary Shares · 100,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100,000 | $43.49 | $4,348,800.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F3 · price: On January 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $43.44 to $43.92. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $3.44 | $344,000.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · derivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,863 Underlying: Ordinary Shares · 100,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100,000 | $43.52 | $4,352,400.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F2 · price: On January 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $43.44 to $43.66. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $3.44 | $344,000.00 |
DisclosureSEC source: 0001209191-19-003938 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 264 | $27.20 | $7,180.80 |
DisclosureSEC source: 0001209191-19-003542 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,164 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2018 through December 31, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 2, 2018. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 795 | $17.26 | $13,717.73 |
DisclosureSEC source: 0001209191-18-042132 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,113 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2018 through June 30, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 2, 2018. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 70,364 | $32.09 | $2,257,699.30 |
DisclosureSEC source: 0001209191-18-040018 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,318 F1 · shares: On June 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 70,364 shares in multiple trades at prices ranging from $32.00 to $32.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,308 | $32.04 | $266,147.61 |
DisclosureSEC source: 0001209191-18-038937 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,682 F2 · price: On June 20, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,308 shares in multiple trades at prices ranging from $32.00 to $32.20. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 621 | $32.00 | $19,872.00 |
DisclosureSEC source: 0001209191-18-038937 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,990 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,289 | $32.00 | $713,248.00 |
DisclosureSEC source: 0001209191-18-038536 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,611 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $32.00 | $6,400.00 |
DisclosureSEC source: 0001209191-18-038045 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,900 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,720 | $32.00 | $375,040.00 |
DisclosureSEC source: 0001209191-18-038045 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,100 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,800 | $32.00 | $89,600.00 |
DisclosureSEC source: 0001209191-18-036187 · doc4.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,820 F5 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 19,694 | $31.64 | $623,118.16 |
DisclosureSEC source: 0001209191-18-036187 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,620 F4 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 19,694 shares in multiple trades at prices ranging from $31.00 to $31.975. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.